Macrophage subpopulations in systemic lupus erythematosus.
暂无分享,去创建一个
[1] S. Gordon,et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth , 2011, The Journal of experimental medicine.
[2] S. Young,et al. Reversal of Hyperlipidemia With a Genetic Switch Favorably Affects the Content and Inflammatory State of Macrophages in Atherosclerotic Plaques , 2011, Circulation.
[3] M. Peters-Golden,et al. Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. , 2011, The Journal of clinical investigation.
[4] M. Lazar,et al. Autoimmune Kidney Disease and Impaired Engulfment of Apoptotic Cells in Mice with Macrophage Peroxisome Proliferator-Activated Receptor γ or Retinoid X Receptor α Deficiency , 2011, The Journal of Immunology.
[5] P. Tak,et al. Statin therapy in lupus-mediated atherogenesis: two birds with one stone? , 2010, Annals of the rheumatic diseases.
[6] J. Auwerx,et al. PPARγ Ligands Switched High Fat Diet-Induced Macrophage M2b Polarization toward M2a Thereby Improving Intestinal Candida Elimination , 2010, PloS one.
[7] Xiao-gang Liu,et al. [Expression and significance of CD80/CD86 in renal tissue of lupus nephritis]. , 2010, Zhonghua nei ke za zhi.
[8] Wei Xu,et al. Blockade of Notch1 Signaling Alleviates Murine Lupus via Blunting Macrophage Activation and M2b Polarization , 2010, The Journal of Immunology.
[9] L. Ivashkiv,et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages , 2010, Proceedings of the National Academy of Sciences.
[10] K. Debatin,et al. Prostaglandin E2 Inhibits IFN-α Secretion and Th1 Costimulation by Human Plasmacytoid Dendritic Cells via E-Prostanoid 2 and E-Prostanoid 4 Receptor Engagement , 2009, The Journal of Immunology.
[11] G. Natoli,et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB , 2009, Proceedings of the National Academy of Sciences.
[12] James L. Park,et al. The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus1 , 2009, The Journal of Immunology.
[13] R. Moots,et al. The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. , 2009, Arthritis and rheumatism.
[14] Y. Jang,et al. Mouse monoclonal autoantibodies penetrate mouse macrophage cells and stimulate NF-kappaB activation and TNF-alpha release. , 2009, Immunology letters.
[15] L. Racusen,et al. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.
[16] Z. Lee,et al. CXCL10 and autoimmune diseases. , 2009, Autoimmunity reviews.
[17] T. Möller,et al. Potent Induction of IFN-α and Chemokines by Autoantibodies in the Cerebrospinal Fluid of Patients with Neuropsychiatric Lupus1 , 2009, The Journal of Immunology.
[18] M. Segal,et al. Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus , 2009, Arthritis Research & Therapy.
[19] K. Walsh,et al. The Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Ameliorates Murine Lupus by Induction of Adiponectin1 , 2009, The Journal of Immunology.
[20] T. Niewold,et al. Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers Increased Sensitivity to IFN-α in Lupus Patients In Vivo1 , 2009, The Journal of Immunology.
[21] B. Croker,et al. Sunlight Triggers Cutaneous Lupus through a CSF-1-Dependent Mechanism in MRL-Faslpr Mice 1 , 2008, The Journal of Immunology.
[22] N. Sebire,et al. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] A. Syvänen,et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5 , 2008, Human molecular genetics.
[24] T. Shin,et al. Prostaglandin E2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice , 2008, Archives of pharmacal research.
[25] E. Bottinger,et al. Activated Renal Macrophages Are Markers of Disease Onset and Disease Remission in Lupus Nephritis1 , 2008, The Journal of Immunology.
[26] A. Scheynius,et al. Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus , 2007, The Journal of experimental medicine.
[27] Wentian Li,et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. , 2007, The New England journal of medicine.
[28] S. Haulon,et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. , 2007, Cell metabolism.
[29] Maria Kavai,et al. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. , 2007, Autoimmunity reviews.
[30] Y. Wang,et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. , 2007, Kidney international.
[31] R. Sinniah,et al. In situ glomerular expression of activated NF-κB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy , 2006, Virchows Archiv.
[32] M. Kretzler,et al. Toll-like receptor-7 modulates immune complex glomerulonephritis. , 2005, Journal of the American Society of Nephrology : JASN.
[33] C. Kallenberg,et al. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement , 2005, Annals of the rheumatic diseases.
[34] Lingyun Sun,et al. Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus , 2005, Clinical Rheumatology.
[35] Silvano Sozzani,et al. The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.
[36] L. See,et al. Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. , 2004, The Journal of rheumatology.
[37] G. Sturfelt,et al. Transcriptional down‐regulation of the platelet ADP receptor P2Y12 and clusterin in patients with systemic lupus erythematosus , 2004, Journal of thrombosis and haemostasis : JTH.
[38] A. Tarakhovsky,et al. IFN-α Priming Results in a Gain of Proinflammatory Function by IL-10: Implications for Systemic Lupus Erythematosus Pathogenesis1 , 2004, The Journal of Immunology.
[39] C. Cohen,et al. CC Chemokine Ligand 5/RANTES Chemokine Antagonists Aggravate Glomerulonephritis Despite Reduction of Glomerular Leukocyte Infiltration1 , 2003, The Journal of Immunology.
[40] Virginia Pascual,et al. Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.
[41] Jiajian Liu,et al. Aberrant Production of IL-12 by Macrophages from Several Autoimmune-Prone Mouse Strains Is Characterized by Intrinsic and Unique Patterns of NF-κB Expression and Binding to the IL-12 p40 Promoter1 , 2002, The Journal of Immunology.
[42] P. Matzinger,et al. Danger signals: SOS to the immune system. , 2001, Current opinion in immunology.
[43] D. Alarcón-Segovia,et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. , 2000, Arthritis and rheumatism.
[44] G. Burmester,et al. Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility , 2000, Annals of the rheumatic diseases.
[45] J. Ragnaud,et al. Th1 (IL‐2, interferon‐gamma (IFN‐γ)) and Th2 (IL‐10, IL‐4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE) , 1999, Clinical and experimental immunology.
[46] D. Beller,et al. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. , 1998, Journal of immunology.
[47] Sun,et al. Expression of Th1/Th2 cytokine mRNA in peritoneal exudative polymorphonuclear neutrophils and their effects on mononuclear cell Th1/Th2 cytokine production in MRL‐lpr/lpr mice , 1998, Immunology.
[48] J. Davoust,et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. , 1998, Arthritis and rheumatism.
[49] D. Klinman,et al. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. , 1996, Arthritis and rheumatism.
[50] Fumihiko Shirakawa,et al. Reduced function of HLA-DR-positive monocytes in patients with systemic lupus erythematosus (SLE) , 1985, Journal of Clinical Immunology.
[51] M. Wagrowska-Danilewicz,et al. Correlative insights into immunoexpression of monocyte chemoattractant protein-1, transforming growth factor beta-1 and CD68+ cells in lupus nephritis. , 2005, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[52] T. Davis,et al. Mice with a regenerative wound healing capacity and an SLE autoimmune phenotype contain elevated numbers of circulating and marrow-derived macrophage progenitor cells. , 2005, Blood cells, molecules & diseases.
[53] R. Evans,et al. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation , 2001, Nature Medicine.
[54] K. Yamane,et al. Decreased release of leukotriene B4 from monocytes and polymorphonuclear leukocytes in patients with systemic lupus erythematosus. , 1991, Arerugi = [Allergy].
[55] D. Pisetsky,et al. Enhanced renal leukotriene production in murine lupus: role of lipoxygenase metabolites. , 1991, Kidney international.